Form 4: Anterix Executive Receives Equity Compensation

Chief Regulatory and Communications Officer Christopher Guttman-McCabe was granted restricted stock units and stock options.

Summary

• Christopher Guttman-McCabe, Chief Regulatory and Communications Officer at Anterix Inc., received an equity grant on May 20, 2026.
• The grant includes 4,926 restricted stock units (RSUs).
• The grant includes 23,271 stock options with an exercise price of $60.90.
• Both the RSUs and stock options vest over a three-year period, beginning May 20, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through multi-year vesting schedules.

Negatives

• Dilutive impact on existing shareholders due to the issuance of new equity and options.

Risks

• Potential for future dilution if options are exercised.

Future Outlook

The equity grants are subject to a three-year vesting schedule, indicating a long-term retention strategy for the executive.

Industry Context

StockSavvy.ai notes that equity-based compensation for C-suite executives is standard practice in the technology and telecommunications sectors to ensure leadership retention and performance alignment.

Comparison to Industry Standards

• The three-year vesting schedule is consistent with standard corporate governance practices for executive compensation packages in the U.S. market.

Stakeholder Impact

• Shareholders may experience minor dilution upon the vesting and potential exercise of these equity instruments.

Next Steps

• Vesting of equity grants beginning May 20, 2027.

Key Dates

Keywords

Anterix, ATEX, Form 4, Insider Trading, Equity Compensation, Stock Options, RSU